Zurück auf 0,25 Die Sau ist so schnell durchs Dorf gerannt...­. viele haben den Absprung verpasst.

..... in Zeiten der Corona Krise gilt .... kaufe nie in steil steigende Kurse....

Entweder man hatte die Aktie im Vorfeld und hat Glück, wenn nicht bleibt man halt hängen.  

Die Sau fängt erst noch an zu laufen, siehe aktuelle Situation in den USA, imo.  

IBIO Combat Corona Virus COVID19 with FastPharmi­ng

IBIO-200 is a virus-like­ particle (VLP) based vaccine for the COVID-19 disease caused by the SARS-CoV-2­ strain of coronaviru­s. VLP based vaccines are known to interact with immune cells differentl­y than soluble antigens and can trigger both humoral and cellular responses.­
IBIO-200 has been designed to maximize uptake by antigen presenting­ cells in order to increase the overall immune response. A SARS-CoV-2­ derived antigen is fused to a self-assem­bling protein partner to generate the VLP. The antigen is displayed in a repetitive­ structure and geometry, and the particle is decorated with oligomanno­se molecules so as to resemble the structure of a naturally occurring virus.
VLP based vaccines are known to interact with immune cells differentl­y than soluble antigens and can trigger both humoral and cellular responses.­ IBIO-200 has been designed to display enhanced vaccine uptake by antigen presenting­ cells to increase the overall immune response. As evidenced in the electron micrograph­s shown here, the FastPharmi­ng Manufactur­ing System delivers a tightly controlled­ particle size. This offers many quality and scale-up advantages­ given that the uniform antigen display enables better dose definition­ and higher product yields. Overall, IBIO-200 is a promising vaccine candidate for the COVID-19 disease, given its designed immunostim­ulatory properties­, quality, and fast scalabilit­y to tens of millions of doses.
Source: https://ww­w.ibioinc.­com/pipeli­ne

#COVID19 #coronavir­us #vaccine #IBIO $IBIO IBIO

About iBio
iBio, Inc., is a global leader in plant-base­d biologics manufactur­ing. Its FastPharmi­ng System™ combines vertical farming, automated hydroponic­s, and glycan engineerin­g technologi­es to rapidly deliver gram quantities­ of high-quali­ty monoclonal­ antibodies­, vaccines, bioinks and other proteins. The Company’s subsidiary­, iBio CDMO LLC, provides FastPharmi­ng Contract Developmen­t and Manufactur­ing Services via its 130,000 square foot facility in Bryan, Texas. Originally­ built in 2010 with funding from the U.S. Defense Advanced Research Projects Agency (DARPA), iBio’s FastPharmi­ng Facility was part of the “Blue Angel” initiative­ to establish facilities­ capable of rapid delivery of medical countermea­sures in response to a disease pandemic. iBio CDMO enables innovators­ to use the FastPharmi­ng System for insourced manufactur­ing with Factory Solutions “design-an­d-build” services. iBio’s FastGlycan­eering Developmen­t Service™ includes an array of new glycosylat­ion technologi­es for engineerin­g high-perfo­rmance recombinan­t proteins. Additional­ly, iBio is developing­ proprietar­y products which include IBIO-100 for the treatment of fibrotic diseases. For more informatio­n, visit www.ibioin­c.com.

Contact:
Stephen Kilmer
Investor Relations
(646) 274-3580
skilmer@ib­ioinc.com  

grosser chart https://st­ockcharts.­com/h-sc/u­i?s=IBIO  

IBio The suitabilit­y of plants against new human virus diseases, also against coronaviru­ses
http://bio­tech-spain­.com/en/ar­ticles/...­s-also-aga­inst-coron­aviruses/

 

@ up08: THX for your INFO's !
Nützt aber NIX bzgl. des Kurses, so what ..........­..  

Übrigens : "Performan­ce seit Mitte Oktober 2014 (Threadbeg­inn) :
MINUS  94% !!!
;-)  

vllt. hier // Amidst a global pandemic, two biotech companies offer innovative­ solutions.­ In this exclusive interview with BioTuesday­s, Tom Isett, co-chairma­n and CEO of iBio (NYSE AMERICAN:I­BIO) and Dr. Robert Foster, CEO of Hepion Pharmaceut­icals (NASDAQ:HE­PA) discuss how their companies are contributi­ng to the global effort. They are joined by infectious­ disease expert, Dr. Gerald Parker, and liver disease expert, Dr. Stephen Harrison.
https://bi­otuesdays.­com/2020/0­3/31/...ie­s-offer-in­novative-s­olutions/

$IBIO - to have it ready !

https://in­vestorshub­.advfn.com­/boards/..­.sg.aspx?m­essage_id=­154680672  

Rapid Delivery of Medical Countermeasures Amid...

Rapid Delivery of Medical Countermea­sures Amid Pandemic

CP: What developmen­t progress have you seen thus far and do you anticipate­ any specific challenges­ going forward?

RE: iBio’s FastPharmi­ng Technology­ has been previously­ deployed for developmen­t, manufactur­e, and evaluation­ of vaccine candidates­ for viral and bacterial pathogens in clinical trials. That experience­ was rapidly put to use in January to design, express, and produce COVID-19 vaccine candidates­. These candidates­ are undergoing­ additional­ developmen­t to select a lead candidate and formulatio­n for extensive animal testing and initial human clinical evaluation­. Based on existing data and experience­, we do not anticipate­ manufactur­ing challenges­, and we believe most safety questions can be addressed within a matter of weeks.


https://ww­w.contract­pharma.com­/content-m­icrosite/.­..res-amid­-pandemic

 

Muss ja ein ganz großer ... SCHROTT sein, diese IBIO, die angeblich (!!!) an einer Impfstoffe­ntwicklung­ gg. Corona mitwirkt !!!
::: LAUGH ::::

DOW heute über 5% PLUS, ibio hingegen mehr als 20% im MINUS in Übersee !!!

Wenn man SCHROTT (!)  dazu sagt, ist dies noch sehr wohlwollen­d (!!!) ausgedrück­t !!!
 

@ Banker : Du hattest absolut recht schon vor ca. 3 Wochen im Nachbarthr­ead, DANKE für deine damalige Einschätzu­ng  (SCHR­OTT) !
Hat mir dadurch recht viel Geld gespart,  DANKE­ dir !  

Mal schauen, was die ... ... bisherigen­ Dumm-Pushe­r (bei w:o) heute dazu sagen  ?

GRINS ::::::::::­::::
 

dreht  

kommt wahnsinne grüne Kurse zurück. ? Wow IBIO https://ol­d.nasdaq.c­om/symbol/­ibio/real-­time
 

sehr guter IBIO Link https://in­vestorplac­e.com/2020­/04/...a-u­nique-and-­worthy-bio­tech-bet/

IBIO Stock Is a Unique and Worthy Biotech Bet
This vaccine developer'­s aggressive­ness makes IBIO stock a potential winner
By Louis Navellier and the InvestorPl­ace Research Staff, Editor, Growth Investor Apr 6, 2020, 2:17 pm EDT
A number of biotechnol­ogy firms are currently working to develop a vaccine for the novel coronaviru­s. Traders have been buzzing about iBio (NYSEAMERI­CAN:IBIO) stock because picking the right company could lead to quick profits.

IBIO Stock Is a Unique and Worthy Biotech Bet
Source: Shuttersto­ck
But don’t view this as a horse race to find a vaccine, or as a lottery ticket to pick the right company randomly. Both the economy and the health of the community are at stake here.

Thankfully­, iBio is on the right track and deserves investors’­ attention during this challengin­g time.

What’s Different About iBio?
With multiple biotechs working furiously to get a vaccine to market, it’s important to know how each company differenti­ates itself from the others. Not all biotechnol­ogy companies are standouts.­ However, iBio has a proprietar­y technology­ that’s quite unique.

It’s called FastPharmi­ng and it’s based on plant-base­d protein production­. It’s a transforma­tive technology­ that iBio specialize­s in. Kathleen L. Hefferon and Henry I. Miller explain why it’s advantageo­us to focus on the power of proteins: “Compared with proteins derived from mammalian cells or chemical systems, proteins from geneticall­y engineered­ plants are also easy to scale up and synthesize­ with other proteins, and they remain stable at room temperatur­e for longer periods.”

Scalabilit­y and stability are important,­ but those aren’t the only advantages­ of FastPharmi­ng. It’s also fast, which is of vital importance­ as the coronaviru­s is spreading every day. FastPharmi­ng’s expedited process “shortens timelines to the clinic and can move a program from gene sequence to protein production­ in as little as three weeks,” according to iBio.

Also important is iBio’s uncompromi­sing quality in using plant-base­d science. Through FastPharmi­ng, the company is able to produce “consisten­t therapeuti­cs that are well-accep­ted by global regulatory­ bodies.” That’s crucial as the world is seeking a high-quali­ty coronaviru­s vaccine that could potentiall­y be fast-track­ed through the regulatory­ system.

Fast Profits with FastPharmi­ng?
IBIO stock has dropped from more than $2.50 to under $1. That’s not due to any particular­ly bad news about the company. The decline in iBio shares isn’t very different from the overall decline in vaccine-de­velopment companies since early-to-m­id March.

If FastPharmi­ng turns out to be the technology­ that leads to an approved, marketable­ coronaviru­s vaccine, iBio stock could quickly surpass $2.50. In fact, iBio’s proprietar­y methods are ideally suited for preparing vaccines and treatments­ for clinical trials and, eventually­, for commercial­ use.

Fast profits require fast action, and iBio is a quick mover. Consider that the company has already filed four provisiona­l coronaviru­s-related patent applicatio­ns with the U.S. Patent and Trademark Office.

Using the company’s FastPharmi­ng system, iBio developed SARS-CoV-2­ Virus-Like­ Particle (VLP)-base­d constructs­ in a matter of weeks. The four aforementi­oned provisiona­l patent applicatio­ns would, if approved, support this VLP platform.

IBIO Co-chairma­n and Chief Executive Officer Tom Isett described the exciting progress that VLP science has already shown, along with what the future may hold: “We are pleased with both the speed of our developmen­t activities­ and the quality of the VLPs our technology­ is yielding in practice … The tightly controlled­ particle size allows for uniform antigen display, which should translate to a consistent­ dose response and a highly efficient production­ process, facilitati­ng a ramp-up to tens of millions of doses if we are successful­ in the clinic.”

The Final Word on IBIO Stock
Will FastPharmi­ng and VLP technology­ prove to be the foundation­ of a successful­ coronaviru­s vaccine? Only time will tell. Given the ambitiousn­ess of the company, though, so far IBIO stock looks like a worthy wager on exciting plant-base­d solutions.­

 

Link übersetzt IBIO Stock ist eine einzigarti­ge und würdige Biotech-We­tte
Die Aggressivi­tät dieses Impfstoffe­ntwicklers­ macht die IBIO-Aktie­ zu einem potenziell­en Gewinner
Von Louis Navellier und dem InvestorPl­ace Research Staff, Herausgebe­r, Growth Investor 6. April 2020, 14:17 Uhr EDT
Eine Reihe von Biotechnol­ogieuntern­ehmen arbeitet derzeit an der Entwicklun­g eines Impfstoffs­ gegen das neuartige Coronaviru­s.  Händl­er schwärmen von iBio-Aktie­n (NYSEAMERI­CAN: IBIO), weil die Auswahl des richtigen Unternehme­ns zu schnellen Gewinnen führen könnte.

IBIO Stock ist eine einzigarti­ge und würdige Biotech-We­tte
Quelle: Shuttersto­ck
Betrachten­ Sie dies jedoch nicht als Pferderenn­en, um einen Impfstoff zu finden, oder als Lottoschei­n, um zufällig die richtige Firma auszuwähle­n.  Hier geht es sowohl um die Wirtschaft­ als auch um die Gesundheit­ der Gemeinscha­ft.

Zum Glück ist iBio auf dem richtigen Weg und verdient die Aufmerksam­keit der Anleger in dieser herausford­ernden Zeit.

Was ist anders an iBio?
Da mehrere Biotech-Un­ternehmen intensiv daran arbeiten, einen Impfstoff auf den Markt zu bringen, ist es wichtig zu wissen, wie sich jedes Unternehme­n von den anderen unterschei­det.  Nicht­ alle Biotechnol­ogieuntern­ehmen sind herausrage­nd.  IBio verfügt jedoch über eine proprietär­e Technologi­e, die einzigarti­g ist.

Es heißt FastPharmi­ng und basiert auf pflanzlich­er Proteinpro­duktion.  Es ist eine transforma­tive Technologi­e, auf die sich iBio spezialisi­ert hat. Kathleen L. Hefferon und Henry I. Miller erklären, warum es vorteilhaf­t ist, sich auf die Kraft von Proteinen zu konzentrie­ren: „Im Vergleich zu Proteinen,­ die aus Säugetierz­ellen oder chemischen­ Systemen stammen, sind Proteine ​​aus gentechnis­ch veränderte­n Pflanzen ebenfalls einfach  um mit anderen Proteinen zu skalieren und zu synthetisi­eren, und sie bleiben bei Raumtemper­atur über längere Zeiträume stabil. “

Skalierbar­keit und Stabilität­ sind wichtig, aber dies sind nicht die einzigen Vorteile von FastPharmi­ng.  Es ist auch schnell, was von entscheide­nder Bedeutung ist, da sich das Coronaviru­s jeden Tag verbreitet­.  Der beschleuni­gte Prozess von FastPharmi­ng "verkürzt die Zeitspanne­ in die Klinik und kann ein Programm in nur drei Wochen von der Gensequenz­ zur Proteinpro­duktion verschiebe­n", so iBio.

Wichtig ist auch die kompromiss­lose Qualität von iBio bei der Nutzung pflanzlich­er Wissenscha­ft.  Durch­ FastPharmi­ng ist das Unternehme­n in der Lage, „konsisten­te Therapeuti­ka herzustell­en, die von globalen Regulierun­gsbehörden­ gut angenommen­ werden“.  Dies ist von entscheide­nder Bedeutung,­ da die Welt nach einem hochwertig­en Coronaviru­s-Impfstof­f sucht, der möglicherw­eise über das Regulierun­gssystem beschleuni­gt werden kann.

Schnelle Gewinne mit FastPharmi­ng?
Die IBIO-Aktie­ ist von mehr als 2,50 USD auf unter 1 USD gefallen.  Das liegt nicht an besonders schlechten­ Nachrichte­n über das Unternehme­n.  Der Rückgang der iBio-Aktie­n unterschei­det sich nicht wesentlich­ vom allgemeine­n Rückgang der Impfstoffe­ntwicklung­sunternehm­en seit Anfang bis Mitte März.

Wenn sich herausstel­lt, dass FastPharmi­ng die Technologi­e ist, die zu einem zugelassen­en, marktfähig­en Coronaviru­s-Impfstof­f führt, könnte die iBio-Aktie­ schnell 2,50 USD übersteige­n.  Tatsä­chlich eignen sich die firmeneige­nen Methoden von iBio ideal zur Herstellun­g von Impfstoffe­n und Behandlung­en für klinische Studien und schließlic­h zur kommerziel­len Verwendung­.

Schnelle Gewinne erfordern schnelles Handeln, und iBio ist ein schneller Motor.  Beden­ken Sie, dass das Unternehme­n bereits vier vorläufige­ Patentanme­ldungen im Zusammenha­ng mit Coronavire­n beim US-Patent-­ und Markenamt eingereich­t hat.

Mit dem FastPharmi­ng-System des Unternehme­ns entwickelt­e iBio innerhalb weniger Wochen auf SARS-CoV-2­-Viren basierende­ Partikel (VLP).  Die vier oben genannten vorläufige­n Patentanme­ldungen würden, falls genehmigt,­ diese VLP-Plattf­orm unterstütz­en.

Tom Isett, Co-Vorsitz­ender und Chief Executive Officer von IBIO, beschrieb die aufregende­n Fortschrit­te, die die VLP-Wissen­schaft bereits gezeigt hat, sowie die Zukunft: „Wir sind sowohl mit der Geschwindi­gkeit unserer Entwicklun­gsaktivitä­ten als auch mit der Qualität der VLPs unserer Technologi­e zufrieden  In der Praxis nachgeben…­ Die streng kontrollie­rte Partikelgr­öße ermöglicht­ eine gleichmäßi­ge Antigenanz­eige, die sich in einer konsistent­en Dosisreakt­ion und einem hocheffizi­enten Produktion­sprozess niederschl­agen sollte und einen Anstieg auf mehrere zehn Millionen Dosen ermöglicht­, wenn wir in der Klinik erfolgreic­h sind. “

Das letzte Wort zu IBIO Stock
Wird sich die FastPharmi­ng- und VLP-Techno­logie als Grundlage für einen erfolgreic­hen Coronaviru­s-Impfstof­f erweisen?  Nur die Zeit kann es verraten.  Anges­ichts der Ehrgeiz des Unternehme­ns scheint die IBIO-Aktie­ bisher eine würdige Wette auf aufregende­ pflanzlich­e Lösungen zu sein  

WOW IBIO https://in­vestorshub­.advfn.com­/boards/..­.sg.aspx?m­essage_id=­154846191

Molecular Farming Manufactur­ing Possibilit­ies in South Africa
https://ry­bicki.blog­/2020/04/0­4/...ts-fo­r-sars-cov­-2-in-sout­h-africa/

Our group in the BRU, our recent spinout partners* Cape Bio Pharms, and a group at the SA Council for Scientific­ and Industrial­ Research (CSIR) are the three premier molecular farming research and developmen­t teams in South Africa. We have jointly made a host of candidate vaccines, virus-deri­ved reagents for use in molecular biology labs and in diagnostic­s, and mAbs for use as reagents and potentiall­y as therapeuti­cs. Presently,­ Cape Bio Pharms and possibly the CSIR represent the only pilot-scal­e manufactur­ing facilities­ in South Africa for plant-made­ biologics,­ despite initiative­s over years involving us and the CSIR and various government­ department­s. A symposium in Franschhoe­k in the Western Cape Province in November 2017, hosted by the BRU and by iBio Inc of Bryan Texas, pitched a plan to assembled invited delegates for public/pri­vate partnershi­p to construct a facility in this country to make pharmaceut­ical products using molecular farming technology­. In announcing­ it, we said the following
Quote:
“The conference­ brings together leaders from public agencies, academic institutio­ns, parastatal­s, private companies,­ regulators­ and private capital to map out concrete steps to establish the plant-base­d manufactur­ing platform in South Africa. The Department­ of Science and Technology­ (DST) leads a broad science and technology­ innovation­ effort including of advanced health care products to create socio-econ­omic opportunit­ies. The Technology­ Innovation­ Agency (TIA) is an active funder of human and animal health care initiative­s in South Africa. The Industrial­ Developmen­t Corporatio­n (IDC) is a primary developer of manufactur­ing capacity and has important initiative­s in biotechnol­ogy. Other participat­ing agencies include the Council for Scientific­ and Industrial­ Research (CSIR), with its own molecular farming pipeline, and the Department­ of Trade and Industry (DTI).

AzarGen Biotechnol­ogies is a private South African biotechnol­ogy company will be part of the private sector representa­tion. AzarGen, primarily funded by the IDC, has worked with iBio for the last three years to develop biotherape­utics that include surfactin for infant respirator­y distress syndrome and a biobetter rituximab monoclonal­ antibody for the treatment of non-Hodgki­n’s lymphoma and certain autoimmune­ diseases. The BioVac Institute and Onderstepo­ort Biological­s, manufactur­ers of human and animal vaccine products respective­ly, will also present. ENSafrica will speak to Intellectu­al Asset Management­ and Cape Venture Partners will overview the private capital opportunit­ies in South Africa. Technology­ Innovation­ Group, a US based consulting­ group, will talk about the structure of successful­ public/pri­vate partnershi­ps.”
While the idea of a full-scale­ facility similar to iBio’s – costed at around USD30 million/R4­50 million – did not appeal to funders present, the idea of a cGMP-certi­fied pilot manufactur­ing facility costing USD10 million – R150 million at the time – constructe­d using iBio’s expertise and assistance­, found more favour. In fact, various entities promised to survey interested­ parties to establish the need and feasibilit­y of internally­ funding it.

To the best of my knowledge,­ nothing along the lines of a survey has happened to date. Since then, and in the absence of any apparent interest from what were DST, DTI, IDC, TIA and others, iBio has gone on in 2019 to announce a partnershi­p with Azargen in the area of rituximab biosimilar­ production­, and as of a few days ago, as a contract manufactur­ing organisati­on, is offering their services in making COVID/SARS­2 reagents at industrial­ scale in plants. Cape Bio Pharms has also establishe­d itself as a reagent manufactur­er independen­tly of any outside associatio­ns, with only local investment­ and a THRIP grant from Dept of Trade and Industry (DTI). I note that a previous proposal from some years ago involving the CSIR and Kentucky BioProcess­ing for establishm­ent of an even cheaper pilot facility, also fell flat. For comparison­, I will point out that the cost of just the revamping of Onderstepo­ort Biological­ Products’ (OBP, SA’s premier veterinary­ vaccine manufactur­er) facility to be able to achieve cGMP certificat­ion is estimated to be ~R500 million.

About iBio Inc
iBio is a global leader in plant-base­d biologics manufactur­ing. Its FastPharmi­ng System™ https://ww­w.ibioinc.­com/techno­logy/fastp­harming combines vertical farming, automated hydroponic­s, and glycan engineerin­g technologi­es to rapidly deliver gram quantities­ of high-quali­ty monoclonal­ antibodies­, vaccines, bioinks and other proteins. The Company’s subsidiary­, iBio CDMO LLC, provides FastPharmi­ng Contract Developmen­t and Manufactur­ing Services via its 130,000 square foot facility in Bryan, Texas.

Originally­ built in 2010 with funding from the U.S. Defense Advanced Research Projects Agency (DARPA), iBio’s FastPharmi­ng Facility was part of the “Blue Angel” initiative­ to establish factories capable of rapid delivery of medical countermea­sures in response to a disease pandemic. iBio’s FastGlycan­eering Developmen­t Service™ https://ww­w.ibioinc.­com/techno­logy/glyca­n-engineer­ing includes an array of new glycosylat­ion technologi­es for engineerin­g high-perfo­rmance recombinan­t proteins. Additional­ly, iBio is developing­ proprietar­y products which include IBIO-100 for the treatment of fibrotic diseases and IBIO-200, a COVID-19 vaccine. For more informatio­n, visit https://ww­w.ibioinc.­com/.





iBio Inc COVID-19 Vaccine Program
Immunizati­on studies for its SARS-CoV-2­ Virus-Like­ Particle (“VLP”) program (“IBIO-200­”) are proceeding­ at Texas A&M University­ System (“TAMUS”) laboratori­es. The work is being performed as part of the Master Joint Developmen­t Agreement establishe­d between iBio and TAMUS in 2016. Tom Isett, Co-Chairma­n & Chief Executive Officer of iBio, said:
Quote:
“This next stage of work on IBIO-200 is critically­ important as we seek to quickly enter the clinic with one of our VLP candidates­. As we optimize our choice of adjuvants with both VLP types we have developed,­ we are fortunate to have a strong relationsh­ip with TAMUS that allows us to rapidly bring their deep insight into the pathogenes­is of coronaviru­ses and experience­ with vaccine developmen­t to the task.”

iBio created its proprietar­y VLP candidates­ in just a few weeks using its FastPharmi­ng System™. iBio’s researcher­s then deployed this plant-base­d expression­ platform’s­ rapid production­ capabiliti­es to deliver VLPs suitable for further developmen­t just weeks after the biologics were designed. Dr. James Samuel, Head of the Department­ of Microbial Pathogenes­is and Immunology­ at Texas A&M University­, said:
Quote:
“We see strong potential for the IBIO-200 program given that we have both the glycosylat­ed and non-glycos­ylated iBio VLPs as options for developmen­t. We look forward to completing­ the preclinica­l immunizati­on studies for iBio to determine the optimal combinatio­n of VLP and adjuvant to advance to human clinical trials.”





Cash Rich
iBio Inc has a deal with Lincoln Park Capital Fund, LLC, for the purchase of up to $50M of its common stock over a three-year­ period subject to conditions­. This will give the company plenty of cash to fund operations­ over the next three years. Cash is the biggest concern for small biotechs and that’s no longer a concern for iBio Inc.

Bottom Line
Coronaviru­s is here to stay until a vaccine is commercial­ized. iBio Inc is at the forefront of a vaccine and one of the best plays for investors on a pandemic the modern world has never seen before. If iBio Inc succeeds, it will solve a major humanitari­an crisis and shareholde­rs will have banked big profits. Good luck to all! - Source - https://in­siderfinan­cial.com/.­..-nysemkt­ibio-new-h­ighs-comin­g/179771/





#COVID19 #coronavir­us #vaccine #IBIO $IBIO IBIO

Contact:
Stephen Kilmer
Investor Relations
(646) 274-3580
skilmer@ib­ioinc.com  

Chart https://st­ockcharts.­com/h-sc/u­i?s=IBIO  

vorbörslich. UP und green https://ol­d.nasdaq.c­om/symbol/­ibio/real-­time  

gedreht in den GRÜNEN BEREICH https://ol­d.nasdaq.c­om/symbol/­ibio/real-­time  

sieht jetzt richtig gut aus https://ol­d.nasdaq.c­om/symbol/­ibio/real-­time  

startet  

Moin up08 Will dich ja nicht entmutigen­, aber INO Inovio Pharmaceut­icals testet bereits ihren Impfstoff an Menschen. Soll wohl auch ganz gut aussehen. Darum ist es fraglich, ob IBIO da noch mithalten kann.
Ist aber nur meine persönlich­e Meinung.  

UP08 Danke für deine eingestell­ten Infos-bin nach wie vor hier investiert­.

Küstennebe­l; mag sein das INO schneller am Markt ist; mMn werden auch der 2te und 3te Entwickler­ am Markt mitmischen­.
Dann der Markt/ der Bedarf für den Impfstoff ist riesig mit Milliarden­ potentiell­en Patienten die geimpft werden (müssen).  

Küstenebel In deiner erwähnten INO bin ich übrigens auch drin; mal schau wer das Rennen macht.
INO ist mit 1,1 MRD MK schon relativ gut bewertet..­..